Latest News | Aurobindo Pharma Arm's New Jersey Unit Gets Warning Letter from USFDA

New Delhi, Oct 22 (PTI) Drug firm Aurobindo Pharma Thursday said its step-down subsidiary has received a warning letter from the US health regulator for its unit in New Jersey, US.

AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey, Aurobindo Pharma said in BSE filing.

Also Read | Sensex Declines Over 250 Points in Early Trade; Nifty Tests 11,850.

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

Aurobindo Pharma said it believes the existing business from this facility will not be impacted.

Also Read | Vivo V20 Pro Smartphone Will Be Launched in India by End of Next of Next Month: Report.

"The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest," it added.

The drug firm, however, did not provide any details of the contents of the warning letter.

Shares of Aurobindo Pharma were trading 3.58 per cent lower at Rs 776.50 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)